Compare PK & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PK | WGS |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Retail: Computer Software & Peripheral Equipment |
| Sector | Real Estate | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2014 | 2020 |
| Metric | PK | WGS |
|---|---|---|
| Price | $15.59 | $64.96 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | $16.18 | ★ $93.50 |
| AVG Volume (30 Days) | ★ 3.2M | 731.3K |
| Earning Date | 11-04-2026 | 10-27-2026 |
| Dividend Yield | ★ 6.59% | N/A |
| EPS Growth | N/A | ★ 62.37 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $2,791,000,000.00 | $427,539,000.00 |
| Revenue This Year | N/A | $12.70 |
| Revenue Next Year | $2.10 | $24.31 |
| P/E Ratio | $52.31 | ★ N/A |
| Revenue Growth | 2.35 | ★ 39.97 |
| 52 Week Low | $9.84 | $32.21 |
| 52 Week High | $16.20 | $170.87 |
| Indicator | PK | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 33.85 |
| Support Level | $14.45 | $56.36 |
| Resistance Level | $15.48 | $73.21 |
| Average True Range (ATR) | 0.38 | 5.42 |
| MACD | -0.02 | -2.04 |
| Stochastic Oscillator | 38.54 | 10.60 |
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 19,902 rooms across 29 hotels in the United States. Park also has an interest through a joint venture in another 1,424 rooms in another US hotel. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under the Hilton brand. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.